The original success of the copyright undeniably revolutionized the drug landscape, but betting in companies primarily reliant on generic versions presents a uncertain picture. Despite early earnings were substantial, the expiration of patents and the emergence of cheaper alternatives have eroded the customer base. Therefore, a thorough assessment